Close menu




October 13th, 2025 | 07:35 CEST

BioNxt Solutions – Attack on new highs

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
  • Cancer
Photo credits: pixabay.com

After global stock markets had been on an upward trajectory in recent weeks, US President Donald Trump caused some irritation with a post on his social media platform, "Truth Social." The escalating trade dispute with China, the world's second-largest economy, caused the already overvalued markets to falter. The DAX lost just under 1.8% at the end of the week, while the Nasdaq technology index suffered significantly more, losing just under 4.3%. In the coming weeks, stock picking is likely to take center stage. Against this backdrop, BioNxt Solutions, a life sciences company specializing in innovative technologies for next-generation drug delivery, was able to shine with fundamental milestones and buck the negative trend.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: Bionxt Solutions Inc. | CA0909741062

Table of contents:


    On track for an all-time high

    Even the emotional post by the energetic US president could not halt the positive development of BioNxt shares. With a closing price of CAD 0.91 on Friday, up 4.6%, the share price is heading towards its all-time high of CAD 1.10. After a correction in mid-September, the share price was able to hold its striking support zone at CAD 0.60 and began a counter-movement amid rising volume. The technical indicators suggest this could be just the beginning. The MACD trend follower generated a buy signal near the zero line last week, while the RSI stands at a moderate 55.74 points and is still far from the overbought range.

    Given the fundamental achievements in recent weeks, this level should certainly serve as an initial interim target, especially given the Company's enormous potential at a market value of CAD 103.20 million.

    text: Source: LSEG as of October 10, 2025

    Attack with MS drug – Fast-track procedure for US patent underway

    In addition to the completed uplisting to the US OTCQB segment and a targeted investor relations offensive, BioNxt shares came into the focus of investors with a milestone announcement. The German-Canadian innovator announced that it had filed a "fast-track" patent application under the so-called Track One program with the US Patent Office for its novel sublingual administration of Cladribine for the treatment of multiple sclerosis (MS). The special feature of this process is the promise of an accelerated review, with a decision expected within the next 9 to 12 months.

    The patented technology is based on an oral thin film that dissolves under the tongue. Cladribine is a proven active ingredient for the treatment of MS. However, in this innovative dosage form, it is expected to act faster, enable better absorption in the body, and, above all, improve treatment compliance. This is particularly relevant for patient groups with swallowing difficulties or those who wish to avoid invasive treatments.

    The application also covers other autoimmune diseases, including myasthenia gravis and lupus nephritis, thus opening up a wide range of applications for the platform technology. Parallel to the US patent application, BioNxt has initiated the patent process in other key regions such as the EU, Canada, Japan, and Australia. Feedback from Europe and Eurasia has already been positive, with the novelty and applicability of the technology being recognized.

    The strategic timing of the application is no coincidence. The final bioequivalence studies and potential partnerships with pharmaceutical companies are imminent. Securing patent protection in good time increases the Company's value and strengthens its negotiating position.

    Watch YouTube video

    Backed by the MS market and ambitions as a takeover candidate

    The multiple sclerosis (MS) market is among the fastest-growing segments in the pharmaceutical industry: in 2024, global sales of MS drugs amounted to around USD 21.1 billion, and forecasts predict that this will almost double to around USD 39 billion by 2032. There is a clear trend toward growing demand for effective, tolerable, and convenient therapies, with nearly half of the revenue coming from the US market alone.

    BioNxt Solutions has strategically positioned itself in this high-growth environment. With its platform technology for sublingual thin films and patches that absorb drugs directly through the mucous membrane or skin, the Company addresses precisely those weak points of traditional dosage forms. Greater comfort, improved bioavailability, and reduced side effects are the key advantages.

    The sublingual administration of cladribine as BNT23001 in the future, for example, opens up a concrete opportunity for market entry in a rapidly growing MS segment, especially at a time when established biologics like Roche's Ocrevus face patent expirations. If BioNxt achieves regulatory approval or at least clinically robust data, the Company would be in the spotlight of large pharmaceutical companies that urgently need new product offensives.

    However, management's ambitions go even further. BioNxt plans to extend its platform technology to other active ingredients, particularly in the areas of obesity, neuroimmune diseases, and oncology. This increases the potential from a single product to a globally scalable platform.


    The current valuation does not yet reflect the strategic value of the technology. If the Company overcomes clinical hurdles, an exit via licensing or direct acquisition by a pharmaceutical or biotech company is entirely plausible. For risk-tolerant investors with an eye on health-tech trends, BioNxt represents one of the most compelling opportunities in the biotech sector today.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read